VALN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

15.00

High

18.00

Current: 0.000

Low

13.00

Averages

15.00

High

18.00

Guggenheim

Buy

downgrade

$14 -> $13

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Jefferies

Maury Raycroft

Buy

downgrade

$18 -> $14

2025-08-25

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $14

2025-08-25

downgrade

Buy

Reason

Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.

H.C. Wainwright

Brandon Folkes

Buy

maintain

$18

2025-08-25

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$18

2025-08-25

maintain

Buy

Reason

H.C. Wainwright analyst Brandon Folkes reiterates a Buy rating on Valneva after the FDA suspended the license for Ixchiq following four new reports of serious adverse events consistent with chikungunya-like illness. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025, the analyst tells investors in a research note. The firm points out that management noted Ixchiq represents a relatively small portion of its near-term revenue expectations. The stock selloff today offers an attractive entry for investors who are constructive on a potential positive readout for VLA15 later this year, contends H.C. Wainwright. It views the selloff as overdone and keeps an $18 price target on Valneva.

H.C. Wainwright

Brandon Folkes

initiated

$18

2025-08-19

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$18

2025-08-19

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Valneva with a Buy rating and $18 price target. The firm says Valneva is a commercial-stage vaccine company with a \"strong proprietary portfolio.\" VLA15 offers a \"de-risked, relatively high-probability path\" to potential blockbuster sales, the analyst tells investors in a research note.

Guggenheim

Vamil Divan

Buy

downgrade

$15 -> $14

2025-05-08

Reason

Guggenheim

Vamil Divan

Price Target

$15 -> $14

2025-05-08

downgrade

Buy

Reason

Guggenheim analyst Vamil Divan lowered the firm's price target on Valneva to $14 from $15 and keeps a Buy rating on the shares. Valneva released detailed Q1 results and provided a corporate update, then announced that the European Medicines Agency is temporarily suspending the use of Valneva's chikungunya vaccine Ixchiq in people over 65 years old as part of the ongoing review of serious adverse events, notes the firm, which is modestly lowering its Ixchiq revenue estimates to account for this new potential safety concern.

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$17

2025-04-15

Reason

HC Wainwright & Co.

Edward White

Price Target

$17

2025-04-15

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is -8.22, compared to its 5-year average forward P/E of -227.03. For a more detailed relative valuation and DCF analysis to assess Valneva SE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-227.03

Current PE

-8.22

Overvalued PE

462.10

Undervalued PE

-916.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.23

Current EV/EBITDA

-21.34

Overvalued EV/EBITDA

54.35

Undervalued EV/EBITDA

-53.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.92

Current PS

3.46

Overvalued PS

5.68

Undervalued PS

2.15

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VALN News & Events

Events Timeline

No data

News

1.0

01-09Globenewswire

Valneva to Showcase Vaccine Progress at J.P. Morgan Conference

1.0

01-09Yahoo Finance

Valneva to Showcase Vaccine Progress at J.P. Morgan Conference

9.5

01-06Benzinga

U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion

People Also Watch

Frequently Asked Questions

What is Valneva SE (VALN) stock price today?

The current price of VALN is 9.87 USD — it has increased 1.23 % in the last trading day.

What is Valneva SE (VALN)'s business?

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

What is the price predicton of VALN Stock?

What is Valneva SE (VALN)'s revenue for the last quarter?

Valneva SE revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?

Valneva SE. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Valneva SE (VALN)'s fundamentals?

The market is revising Downward the revenue expectations for Valneva SE (VALN) for FY2025, with the revenue forecasts being adjusted by -5.54% over the past three months. During the same period, the stock price has changed by -11.40%.

How many employees does Valneva SE (VALN). have?

Valneva SE (VALN) has 676 emplpoyees as of January 10 2026.

What is Valneva SE (VALN) market cap?

Today VALN has the market capitalization of 849.26M USD.